|
| Study | Year | Country | Number of patients (NSAIDs/control) | Intervention | Definition of post-ERCP pancreatitis | Inclusion criteria | Study design | Adverse events attributed to rectal NSAID administration |
|
| Andrade-Dávila et al. [15] | 2015 | Mexico | 166 (82/84) | Indomethacin (or placebo), rectally, 100 mg after ERCP | Amylase or lipase > 3 ULN within 24 h after ERCP and abdominal pain | High-risk patients | RCT TB MC | Itching in the anus in 2 patients in each group and there was no mortality |
| Döbrönte et al. [6] | 2014 | Hungary | 665 (347/318) | Indomethacin (or placebo), rectally, 100 mg, before ERCP | Amylase and/or lipase > 3 ULN within 24 h after ERCP and abdominal pain | All-risk patients | RCT TB MC | None in both groups |
| Elmunzer et al. [10] | 2012 | USA | 602 (295/307) | Indomethacin (or placebo), rectally, 100 mg after ERCP | Amylase > 3 ULN within 24 h after ERCP, new upper abdominal pain, and hospitalization for at least 2 nights | High-risk patients | RCT DB MC | None in both groups |
| Khoshbaten et al. [11] | 2008 | Iran | 100 (50/50) | Diclofenac (or placebo), rectally, 100 mg after ERCP | Amylase > 4 ULN, epigastric or back pain, and epigastric rebound tenderness | High-risk patients | RCT DB SC | None in both groups |
| Levenick et al. [8] | 2016 | USA | 449 (223/226) | Indomethacin (or placebo), rectally, 100 mg during ERCP | Lipase > 3 ULN within 24 h after ERCP and abdominal pain | All-risk patients | RCT DB SC | None in both groups |
| Montaño et al. [16] | 2007 | Mexico | 150 (75/75) | Indomethacin (or placebo), rectally, 100 mg before ERCP | Amylase > 3 ULN, sharp pain radiating to the back, and nausea/vomiting | All-risk patients | RCT SB MC | None in both groups |
| Murray et al. [12] | 2003 | Scotland | 220 (110/110) | Diclofenac (or placebo), rectally, 100 mg after ERCP | Amylase > 4 ULN, epigastric or back pain, and epigastric rebound tenderness | High-risk patients | RCT DB SC | None in both groups |
| Otsuka et al. [13] | 2012 | Japan | 104 (51/53) | Diclofenac (or placebo), rectally, 50 or 25 mg, before ERCP | Amylase > 3 ULN within 24 h after ERCP and abdominal pain | All-risk patients | RCT DB MC | None in both groups |
| Patai et al.[17] | 2015 | Hungary | 539 (270/269) | Indomethacin (or placebo), rectally, 100 mg, after ERCP | Amylase > 3 ULN within 24 h after ERCP | All-risk patients | RCT DB SC | None in both groups |
| Shafique et al. [14] | 2016 | Pakistan | 108 (54/54) | Diclofenac (or placebo), rectally, 100 mg, before ERCP | Amylase > 4 ULN, epigastric pain with guarding and/or vomiting, | All-risk patients | RCT DB SC | None in both groups |
| Sotoudehmanesh et al. [18] | 2007 | Iran | 442 (221/221) | Indomethacin (or placebo), rectally, 100 mg, before ERCP | Amylase > 3 ULN, epigastric or back pain, and epigastric tenderness | All-risk patients | RCT DB SC | None in both groups |
|
